Publications

Featured Publications

Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2023


>> View Poster

ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer

Future Oncology

calendar icon June 2023


>> View Article

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon


>> View Presentation

All Publications

  • Filter by Indications

  • Filter by Clinical Study

  • Reset Filters

Intravenous Administration of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in a Phase 1/2 Study of Patients With Advanced Solid Tumors

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon May 2019


>> View Poster

Peripheral Blood Lymphocyte Response to High Dose IL2 in RCC

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2018


>> View Poster

Pharmacokinetics and Pharmacodynamic Effects of ALKS 4230, an Investigational Immunotherapeutic Agent, in Cynomolgus Monkeys After Intravenous and Subcutaneous Administration

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2018


>> View Poster

Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALKS 4230 in Patients With Advanced Solid Tumors From the Ongoing Dose Escalation Portion of a First In Human (FIH) Study

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2018


>> View Poster

A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2017


>> View Poster

A Phase 1 Trial of ALKS 4230, an Engineered Cytokine Activator of NK and Effector T Cells, in Patients with Advanced Solid Tumors

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2017


>> View Poster

First-In-Human Dose Selection for ALKS 4230, an Investigational Immunotherapeutic Agent

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2017


>> View Poster

Efficacy of ALKS 4230, a Novel Immunotherapeutic Agent, in Murine Syngeneic Tumor Models Alone and in Combination with Immune Checkpoint Inhibitors

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2017


>> View Poster

Characterization of the Pharmacodynamic Immune Response to a Novel Immunotherapeutic Agent, ALKS 4230, in Mice and Non-Human Primates

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2017


>> View Poster